Angiochem's ANG1005 nearing start of Phase 3

Welcome to the Bioasis Technologies Hub On AGORACOM

Reply New Message

Prev Message Back To Forum Threaded View Next Message

BearDownAZ

Rank: President [?]

Points: 25003 [?]

Votes: 68 Score: 4.5 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Angiochem's ANG1005 nearing start of Phase 3

posted on Dec 21, 2016 03:45PM

An update on one of biOasis' competitors, Angiochem:

Results from Angiochem's Phase 2 Trial of their Angiopep-2 peptide-Paclitaxel conjugate in patients with breast cancer brain metastases and leptomeningeal carcinomatosis were presented at a couple of meeting this fall and summarized in an October news release entitled "Angiochem's ANG1005 Shows Clinical Benefits and Prolonged Survival for Breast Cancer Patients With Brain Metastases." They are working towards launching a Phase 3 trial next year.

Angiochem still lists their HER2-antibody conjugate and enzyme replacement LSD programs as pre-clinical.

Reply New Message

Prev Message Back To Forum Threaded View Next Message

Please to post a reply